The incidence of invasive fungal infections (IF1) has increased sub stmltially during tile past 30 years. CulTently, fungal infections are among tile most common causes of morbidity mid mortality in patients with hematological malignancies or those undergoing atem cell transplantation (SCT). It is estimated that IFI develops in 10 25% of patients with acute leukemia and those receiving SCT. The ease fatality rate exceeds 50% and is approximately 90% in invasive aspergillosis, especially in patients with peizistent neutropenia. Tile role of persistent neutropenia for tile development of IFI has been well established. Tile other risk factors include: previous fungal infection, environmental exposure, the long term use of broad spectrum antibiotics, steroids, or chemotherapeutic agents, and the use of the high technology invasive monitoring. Camlida and Aspergillus species traditionally account for tile majority of documented infections. However, recent epidemiologica[ reports indicate an incleasing incidence of infections with Aspergillus spp., and a shift towards non-albicans Caruiida and other emerging fungi such as Fusarium, Scedosporium, Trichospororz, and Mucor spp. Infections by these pathogens have extraordinarily high ease fatality rates. Although a number of new antifungal agents have been available recently for treatment, in most of the eases survival is strongly associated with recovery from neutropenia mid/or remission of tile underlying diseases.
Full conference title:
International Congress on Chemotherapy, 24th Meeting
- ICC 24 th